

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5495817

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BO LIANG	04/26/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	IVIEW THERAPEUTICS, INC.
<b>Street Address:</b>	3805 OLD EASTON ROAD
<b>Internal Address:</b>	PENNSYLVANIA BIOTECHNOLOGY CENTER AT BUCKS COUNTY
<b>City:</b>	DOYLESTOWN
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	18902
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
PCT Number:	US2018049333
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3127749465
<b>Email:</b>	ipmail@venturepartnerllc.com
<b>Correspondent Name:</b>	VENTURE PARTER LLC.
<b>Address Line 1:</b>	401 N MICHIGAN AVE.
<b>Address Line 2:</b>	SUITE 1200
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60611
<b>ATTORNEY DOCKET NUMBER:</b>	146660-011900
<b>NAME OF SUBMITTER:</b>	WEISUN RAO
<b>SIGNATURE:</b>	/Weisun Rao/
<b>DATE SIGNED:</b>	04/26/2019
<b>Total Attachments: 2</b>	
source=146646-012200_assignment_asFiled_to_record#page1.tif	
source=146646-012200_assignment_asFiled_to_record#page2.tif	

**ASSIGNMENT**

WHEREAS, I, **Bo Liang**, a US citizen (hereinafter "**ASSIGNOR**"), for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to **IVIEW Therapeutics, Inc.**, a company organized and existing under the laws of the United States of America, with an address at Pennsylvania Biotechnology Center at Bucks County, 3805 Old Easton Road, Doylestown, PA 18902, USA; its respective successor(s) and assign(s), all hereinafter referred to as the "**ASSIGNEE**";

(1) my entire right, title and interest in the United States and all other countries throughout the world in and to any and all of our inventions and discoveries disclosed in the following patent applications (collectively, the "**Patent Applications**");

(a) US Application No. 62/553,806, filed on September 2, 2017, and entitled "In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis";

(b) International Patent Application No. **PCT/US2018/049333**, entitled "IN SITU GEL-FORMING PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR SINUS DISEASES," filed with the US Receiving office on **September 4, 2018**;

(c) United States Patent Application No. **16/345,634**, entitled "IN SITU GEL-FORMING PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR SINUS DISEASES," filed with the United States Patent and Trademark Office on **04/26/2019**;

(d) European Patent Application No. 18852534.9, entitled "IN SITU GEL-FORMING PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR SINUS DISEASES," filed with the European Patent Office on April 18, 2019;

(e) any and all applications claiming priority to or based on any of the applications identified above in (a), (b), (c), and (d), including but not limited to national or regional phase applications based on PCT/US2018/049333, divisional, continuation, or continuation-in-part of such national or regional phase applications;

(2) my full and complete right to file patent applications claiming priority to or based on the Patent Applications in the name of the ASSIGNEE, its designee, or at the election of the ASSIGNEE or its designee, in the United States and any other country of the world, or to file one or more international

applications claiming priority to or based on the Letters Patent or Patent Applications identified above under any international treaty such as the Patent Cooperation Treaty; and


(3) my entire right, title and interest in and to any Letters Patent which may issue from – either directly or indirectly (through priority claim) – the Patent Applications, and in and to any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisionals thereof.

I hereby agree that prior to the filing of the Patent Applications, all of my rights, title, and interest in and to the Letters Patent and Patent Applications and any future patent applications claiming priority thereto or based thereon (including any International Patent Applications and any national phase filing therefrom for the inventions or discoveries disclosed or described in the Letters Patent or Patent Applications) were vested in the ASSIGNEE.

I agree, at any time, upon the request of the ASSIGNEE to execute and to deliver to the ASSIGNEE any additional applications for patents for the inventions and/or discoveries disclosed in the Patent Applications, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on the inventions and/or discoveries of the Patent Applications.

I further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on the inventions and/or discoveries in the Patent Applications and any patent applications claiming priority thereto or based thereon throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.


**Agreed and Accepted by Assignor:**

  
\_\_\_\_\_

Bo LIANG

Date: 04/26/19

**Acknowledged by Assignee (IVIEW Therapeutics, Inc.):**

  
\_\_\_\_\_

Date: 04/26/19